Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0000950170-22-018295
Filing Date
2022-09-09
Accepted
2022-09-09 16:15:27
Documents
14
Period of Report
2021-12-31

Document Format Files

Seq Description Document Type Size
1 10-K/A fstx-20211231.htm   iXBRL 10-K/A 127046
2 EX-31.1 fstx-ex31_1.htm EX-31.1 25752
3 EX-31.2 fstx-ex31_2.htm EX-31.2 25868
  Complete submission text file 0000950170-22-018295.txt   382515

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT fstx-20211231_pre.xml EX-101.PRE 17874
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT fstx-20211231.xsd EX-101.SCH 2577
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT fstx-20211231_lab.xml EX-101.LAB 29138
8 EXTRACTED XBRL INSTANCE DOCUMENT fstx-20211231_htm.xml XML 10184
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

EIN.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-37718 | Film No.: 221236359
SIC: 2834 Pharmaceutical Preparations